Home > Insider Trading > Filing (0001209191-17-052684)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1274792	Merrimack Pharmaceuticals Inc	MACK	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1531962	B. Ulrik Nielsen	C/O Merrimack Pharmaceuticals, Inc. One Kendall Square, Suite B7201 Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-09-11	14,756	$13.20	37,437	No	4	M	Direct
Common Stock	Disposition	2017-09-11	14,756	$14.46	22,681	No	4	S	Direct
Common Stock	Acquisiton	2017-09-13	6,800	$13.20	29,481	No	4	M	Direct
Common Stock	Disposition	2017-09-13	6,800	$14.27	22,681	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2017-09-11	14,756	$0.00	14,756	$13.20
Common Stock	Stock Option (right to buy)	Disposition	2017-09-13	6,800	$0.00	6,800	$13.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
14,033		2017-10-04	No	4	M	Direct
7,233		2017-10-04	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.43 to $14.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.15 to $14.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The one-for-ten reverse stock split of the Issuer's common stock that became effective for trading purposes on September 6, 2017 resulted in the reporting person's ownership of 204,130 fewer shares of common stock.
This option was previously reported as covering 146,622 shares of common stock at an exercise price of $2.59 per share, but was adjusted to reflect both the special cash dividend that was payable on May 26, 2017 and the reverse stock split that became effective for trading purposes on September 6, 2017.
This option is fully vested.